RedHill Biopharma’s (RDHL) “Outperform” Rating Reaffirmed at FBR & Co
RedHill Biopharma Ltd. (NASDAQ:RDHL)‘s stock had its “outperform” rating reissued by equities research analysts at FBR & Co in a research note issued on Wednesday. They currently have a $36.00 target price on the stock. FBR & Co’s price objective would indicate a potential upside of 152.26% from the company’s current price.
Several other equities analysts have also commented on RDHL. Zacks Investment Research lowered shares of RedHill Biopharma from a “buy” rating to a “hold” rating in a report on Wednesday, July 6th. HC Wainwright set a $33.00 price objective on shares of RedHill Biopharma and gave the stock a “buy” rating in a report on Friday, October 7th. One equities research analyst has rated the stock with a hold rating and five have issued a buy rating to the company. The stock has an average rating of “Buy” and an average target price of $26.20.
Shares of RedHill Biopharma (NASDAQ:RDHL) traded up 1.7170% during midday trading on Wednesday, reaching $14.2709. 13,925 shares of the company’s stock traded hands. RedHill Biopharma has a 1-year low of $8.10 and a 1-year high of $16.54. The stock’s market capitalization is $181.73 million. The firm’s 50-day moving average price is $14.63 and its 200 day moving average price is $12.81.
This story is the sole property of American Banking News and it was originally published by American Banking News. If you are reading this story on another website, that means this article was illegally copied and re-published to this website in violation of U.S. and International copyright law. The original version of this article is available at https://www.americanbankingnews.com/2016/10/12/redhill-biopharmas-rdhl-outperform-rating-reaffirmed-at-fbr-co.html
RedHill Biopharma (NASDAQ:RDHL) last issued its quarterly earnings data on Wednesday, July 27th. The company reported ($0.06) EPS for the quarter, topping the consensus estimate of ($0.58) by $0.52. On average, equities analysts predict that RedHill Biopharma will post ($2.06) earnings per share for the current fiscal year.
A number of large investors have recently made changes to their positions in the company. Van ECK Associates Corp increased its stake in shares of RedHill Biopharma by 1.5% in the second quarter. Van ECK Associates Corp now owns 9,623 shares of the company’s stock valued at $105,000 after buying an additional 138 shares during the last quarter. Ingalls & Snyder LLC acquired a new stake in shares of RedHill Biopharma during the second quarter valued at $451,000. Oppenheimer & Co. Inc. acquired a new stake in shares of RedHill Biopharma during the second quarter valued at $142,000. Finally, Royal Bank of Canada increased its stake in shares of RedHill Biopharma by 0.9% in the first quarter. Royal Bank of Canada now owns 21,167 shares of the company’s stock valued at $259,000 after buying an additional 191 shares during the last quarter. 15.30% of the stock is currently owned by hedge funds and other institutional investors.
RedHill Biopharma Company Profile
Receive News & Ratings for RedHill Biopharma Ltd. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for RedHill Biopharma Ltd. and related companies with MarketBeat.com's FREE daily email newsletter.